Purchase this article with an account.
S. T. Lee, R. A. Adelman; The Treatment of Recurrent Central Serous Chorioretinopathy With Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1329.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the effect of intravitreal bevacizumab injection in recurrent central serous chorioretinopathy (CSC).
A retrospective study of patients who were followed at the Yale Eye Center with a diagnosis of recurrent CSC who were treated with intravitreal bevacizumab from January 2007-January 2009. 1.5 mg injections of bevacizumab were given once every 4 weeks until sub-retinal fluid resolved. We collected pre-injection visual acuity, optical coherence tomography (OCT), fluorescein angiography imaging, number of injections administered, OCT data after each injection, and visual acuity after each injection. Each patient was followed for a minimum of 6 months.
Three patients met the inclusion criteria. All patients were male and ages ranged from 39-46 years of age. All patients had recurrent disease. Mean pre-injection logMAR visual acuity was 0.30, with a median of 0.30. Mean post-bevacizumab visual acuity was 0.03, 0.07, 0.03 at 1, 3, and 6 months respectively. Median post-bevacizumab logMAR visual acuity was 0, 0.10, and 0 at 1, 3, and 6 months respectively. Baseline pre-injection central macular thickness (CMT) by OCT imaging ranged from 320µ-500µ, with a mean of 388µ and a median of 344µ. Mean CMT at month 1 was 248µ, with a median of 190µ. Mean CMT at month 3 was 252µ, with a median of 281µ. Mean CMT at month 6 was 273µ, with a median of 187µ.
Intravitreal bevacizumab may be an effective treatment option for patients with recurrent CSC. Although long-term efficacy is unknown, it is a relatively low-risk treatment option that may improve visual acuity and CMT.
This PDF is available to Subscribers Only